Brief: Angle Signs New Commercial Agreement With Astrazeneca
24/04/2024 07:44
April 24 (Reuters) - Angle PLC AGLE.L :
* NEW COMMERCIAL AGREEMENT WITH ASTRAZENECA
* SIGNS AGREEMENT TO TAILOR EXISTING PARSORTIX-BASED DNA
DAMAGE
RESPONSE ASSAY FOR USE IN PHARMACEUTICAL RESEARCH AND
DEVELOPMENT
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cellbxhealth
See all newsBrief: Cellbxhealth Anticipates FY2027 Revenues Of £3 Million-£4 Million
Brief: Cellbxhealth Enters Master Services Agreement With Swiss Biotech
Master Services Agreement with Swiss biotech co
Q3 Trading Update and FY 2026 Outlook
Brief: Cellbxhealth Signs New Statement Of Work With US-Based Pharma Company